Erimos Technologies is a biopharmaceutical company based in Houston, TX, dedicated to the discovery and development of small molecule therapeutics for the treatment of cancer and viral diseases. Their lead product, Terameprocol, has shown promising results in inhibiting the expression of specific proteins over-expressed in cancer and has demonstrated long-term tolerability and anti-tumor activities in clinical studies.
With a focus on cutting-edge research, Erimos has partnered with leading institutions, including the Johns Hopkins University, to conduct clinical trials and develop innovative treatments. They are actively seeking partnerships for the development and commercialization of Terameprocol for various diseases, including solid tumors, hematological malignancies, pre-neoplastic conditions, and viral infections.
Generated from the website